• Histological, pathological, and/or cytological confirmation of adenocarcinoma of the prostate

• ECOG performance status 0 to 1

• Criteria specific for patients with mCRPC:

‣ Previously received an androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy (unless ineligible or refused taxane). Received a maximum of 3 prior systemic therapy regimens in the mCRPC setting

⁃ Progressive mCRPC at the time of consent based on at least 1 of the following criteria being met in the context of castrate levels of testosterone:

• PSA progression defined as rising PSA values at a minimum of 1-week intervals, with the last result being at least 1.0 ng/mL

∙ Soft-tissue progression defined as an increase ≥20% in the sum of the diameter (SOD) (short axis for nodal lesions and long axis for non-nodal lesions) of all target lesions based on the smallest SOD since treatment started or the appearance of one or more new lesions

∙ Progression of bone disease defined as the appearance of two or more new lesions by bone scan

⁃ At least one PSMA-PET positive lesion for prostate cancer

⁃ Castrate circulating testosterone levels (\<1.74 nmol/L or \<50 ng/dL)

• Criteria specific for patients with OmHSPC:

‣ PSA recurrence after radical prostatectomy (RP) or definitive radiation therapy (RT), with or without adjuvant/salvage local therapy (radiation or surgery), with or without (neo)adjuvant ADT

• PSA ≥ 0.2ng/mL for patients with prior RP +/- RT, or

∙ PSA of ≥ 2 ng/mL above nadir for patients with only prior RT

⁃ 1- 5 PSMA-PET positive lesions identified outside the prostate bed or remaining gland.